Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ZEVRA THERAPEUTICS, INC.
Report date December 31, 2025 · Filed January 07, 2026
Section 16 reporting ended · disclosed 2026-01-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 143,515 |
Ending reported balance
After 2025-12-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-31 · Exercise / conversion · Acquired 140,667 · Balance 192,028 F1: Shares issued upon vesting of restricted stock units and performance stock units on December 31, 2025. Row 2 · 2025-12-31 · Tax withholding · Disposed 48,513 · Balance 143,515 F2: Shares withheld to cover withholding taxes for the vested restricted stock units and performance stock units. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-12-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-31 · Exercise / conversion · Disposed 86,667 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-12-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-31 · Exercise / conversion · Disposed 34,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. |
| Performance Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-12-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-31 · Exercise / conversion · Disposed 20,000 · Balance 0 F5: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock. F4: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issued upon vesting of restricted stock units and performance stock units on December 31, 2025.
F2: Shares withheld to cover withholding taxes for the vested restricted stock units and performance stock units.
F3: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F4: The vesting of all restricted stock units and performance stock units was accelerated upon the Reporting Person's departure from the Company on December 31, 2025.
F5: Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 25, 2018 Filed Jan 29, 2018 18:56 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001437749-18-001303 · rdgdoc.xml · derivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 25, 2019 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| September 25, 2017 Filed Sep 25, 2017 16:33 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 300 | $3.78 | $1,132.50 |
DisclosureSEC source: 0001437749-17-016324 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 08:57 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 275 | $3.30 | $907.50 |
DisclosureSEC source: 0001437749-17-011574 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275 Read SEC document |
| March 24, 2017 Filed Mar 27, 2017 16:28 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 100 | $4.24 | $424.36 |
DisclosureSEC source: 0001437749-17-005323 · rdgdoc.xml · nonDerivative · entry 2 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| March 24, 2017 Filed Mar 27, 2017 16:28 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 900 | $4.24 | $3,819.33 |
DisclosureSEC source: 0001437749-17-005323 · rdgdoc.xml · nonDerivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 16:58 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001437749-17-001389 · rdgdoc.xml · derivative · entry 1 Clifton R. LaDuane · CIK 0001488774 · CFO, Secretary & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-01-26 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 27, 2018 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.